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Abstract Osteomyelitis is a serious infection predominantly
caused by Gram-positive bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA). Orthopaedic
device-related infections are complex and require a careful
combination of surgical intervention and antimicrobial thera-
py. Daptomycin, a cyclic lipopeptide, effectively penetrates
soft tissue and bone and demonstrates rapid concentration-
dependent bactericidal activity against Gram-positive patho-
gens. This retrospective, non-interventional study evaluated
clinical outcomes in patients with osteomyelitis or orthopaedic
device infections treated with daptomycin from the European
Cubicin® Outcomes Registry and Experience (EU-CORESM)
study. Patients were treated between January 2006 and April
2012, with follow-up to 2014. Clinical outcomes were
assessed as success (cured or improved), failure or non-
evaluable. Of 6,075 patients enrolled, 638 (median age,
63.5 years) had primary infections of osteomyelitis or ortho-
paedic device infections, 224 had non-prosthetic osteomyeli-
tis, 208 had osteomyelitis related to a permanent or temporary
prosthetic device, and 206 had orthopaedic device infections.
The most commonly isolated pathogen was S. aureus (214
[49.1 %]; 24.8%wereMRSA). Overall, 455 (71.3 %) patients
had received previous antibiotic therapy. Patients underwent
surgical interventions, including tissue (225 [35.3 %]) and
bone (196 [30.7 %]) debridement, as part of their treatment.
Clinical success rates were 82.7 % and 81.7 % in S. aureus
and coagulase-negative staphylococcal infections. Adverse
events (AEs) and serious AEs assessed as possibly related to
daptomycin were observed in 6.7 % and 1.9 % of patients,
respectively. Daptomycin was discontinued by 5.5 % of pa-
tients due to AEs and 10 (1.6 %) deaths were reported. In
conclusion, daptomycin was effective and safe in patients with
osteomyelitis or orthopaedic device infections.
Introduction
Osteomyelitis is associated with inflammatory changes in
bone tissue accompanying bone destruction due to pyogenic
organisms. Infections may complicate a variety of factors such
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as trauma, surgery to the skeleton, and implant replacement
surgery [1, 2]. Staphylococcus aureus is the most frequently
implicated pathogen in osteomyelitis and coagulase-negative
staphylococci (CoNS) the most common in prosthetic joint
and device-related infections [1, 3]. Other Gram-positive and
Gram-negative organisms may be less frequently involved
[2]. The most important factor in the development of chronic
osteomyelitis is the production of a biofilm [4]. Once
established, biofilms are difficult to eradicate due to the lack
of drug penetration, drug inactivation, or physiological state of
bacteria within the biofilm [5].
Despite advances in medical and surgical therapies, osteo-
myelitis remains difficult to treat and is responsible for signif-
icant morbidity [6]. The risk and severity of infection can be
increased by the presence of a foreign body, such as metallic
or prosthetic devices [7]. Treatment of osteomyelitis is com-
plex, usually requiring a specific antibiotic regimen and often
necessitating surgery for the removal of any infected bone or
soft tissue, including temporary or permanent removal of the
implant, or a combination of debridement with implant reten-
tion and long-term antimicrobial therapy [8, 9]. Using antibi-
otic combinations and choosing an optimal surgical procedure
can eradicate orthopaedic implant-associated infections in 80–
90% of patients [10]. However, relapse rates can be high even
after seemingly successful antibiotic treatment [11].
Daptomycin, a cyclic lipopeptide, displays rapid
concentration-dependent bactericidal activity against a wide
range of Gram-positive pathogens. Daptomycin penetrates
bone and synovial fluid effectively [12] and has demonstrated
efficacy in animal models of chronic methicillin-resistant
S. aureus (MRSA) osteomyelitis [13]. Daptomycin is ap-
proved in adult patients, at a dose of 4 mg/kg/day for the
treatment of complicated skin and soft tissue infections caused
by Gram-positive bacteria, and at 6 mg/kg/day for right-sided
endocarditis due to S. aureus and for bacteraemia associated
with complicated skin and soft tissue infections or right-sided
endocarditis [14]. The combination of daptomycin and rifam-
pin has been proposed as a potentially good option for treating
staphylococcal-biofilm-related infection [15] as these two
agents are synergistic in vitro and both disrupt and inhibit
biofilm production [16]. This combination could also reduce
the likelihood of S. aureus resistance, particularly when com-
bined with early surgical debridement [17].
There have been a number of published case series
reporting clinical improvement in patients with osteomyelitis
treated with daptomycin [18–20]. The Infectious Diseases
Society of America (IDSA) guidelines for the management
of MRSA infections recognize daptomycin as an antibiotic
option for the treatment of osteomyelitis [21] and the IDSA
guidelines for the management of prosthetic joint infections
also recommend daptomycin as an alternative to oxacillin and
vancomycin [22]. Interim data from the first 220 patients with
osteomyelitis, non-prosthetic, and temporary or permanent
device-related infection, treated with daptomycin and enrolled
in the European Cubicin® Outcomes Registry and Experience
(EU-CORESM) registry suggested that daptomycin is an effec-
tive and well-tolerated treatment option for osteomyelitis with
a follow-up of at least 30 days post-treatment [23]. The objec-
tive of the present analysis was to evaluate the effectiveness
and safety of daptomycin in a lager cohort of patients with
primary infections of osteomyelitis, non-prosthetic and pros-
thetic device-related, or orthopaedic device infections, en-
rolled in the EU-CORE registry and followed for up to 2 years
after the end of daptomycin therapy.
Methods
Patients
EU-CORE was a non-interventional, multicentre, retrospec-
tive study that collected real-world outcome data from patients
receiving at least one dose of daptomycin for the treatment of
serious Gram-positive bacterial infections. Among them, all
patients with primary infections of osteomyelitis (non-pros-
thetic and prosthetic device-related) or orthopaedic device in-
fections were included in this analysis.
Data collection
A protocol and standardised case report form were used to
collect demographic and clinical information on patients
who had been treated with daptomycin between January
2006 and April 2012. All data were collected from themedical
records of the patients enrolled. Patients with osteomyelitis or
orthopaedic device infections were followed for up to two
years until 2014. The complete data collection methodology
has been described previously [24].
The study was conducted according to the ethical princi-
ples of the Declaration of Helsinki. The protocol was ap-
proved by the health authority and the Institutional Review
Board (IRB) or Ethics Committee (EC) in each country and
written informed consent was obtained from patients/legally
acceptable representatives of patients according to the require-
ments of the IRB or EC and/or the local data privacy
regulations.
Clinical outcomes
Clinical outcomes were assessed at the end of daptomycin
therapy and at the 12- and 24-month follow-up time points
according to the following protocol-defined criteria: cured,
clinical signs and symptoms resolved, no additional antibiotic
therapy was necessary, or infection cleared with a negative
culture reported; improved, partial resolution of clinical signs
and symptoms and/or additional antibiotic therapy was
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warranted; failed, inadequate response to daptomycin therapy,
worsening or new/recurrent signs and symptoms, need for a
change in antibiotic therapy, or a positive culture reported at
the end of therapy; and non-evaluable, unable to determine
response due to insufficient information. Clinical success
was defined as patients who were cured or improved. The time
to improvement was also recorded. The reasons for stopping
daptomycin therapy and other antibiotics prescribed following
daptomycin were also collected [24].
Safety
The investigators assessed adverse events (AEs) and serious
AEs (SAEs) for 30 days post-treatment. All reported AEs,
regardless of their relationship to daptomycin, were recorded
and their severity was determined by the local investigators.
Statistical analysis
Statistical analysis was performed using SAS version 9.3
(SAS Institute Inc., Cary, NC, USA). Inferential analyses were
not conducted and only descriptive statistics were used. All
analyses were considered to be explanatory. Numerical vari-
ables were expressed as arithmetic mean, standard deviation,
median, minimum, first quartile, third quartile, and maximum
for continuous variables. Categorical variables were summa-
rized by absolute and relative frequencies.
Results
Patient demographics and clinical characteristics
A total of 6,075 patients were enrolled in the EU-CORE reg-
istry, of whom 638 (10.5 %) had osteomyelitis (non-prosthetic
and prosthetic device-related) and orthopaedic device infec-
tions. The patients were predominantly Caucasian (n=536;
84.0 %) with a median age of 63.5 years (range, 8–93) and a
median body weight of 76.0 kg (range, 24–136). Of the 638
patients, 432 (67.7 %) had osteomyelitis and 206 (32.3 %) had
orthopaedic device infections. Osteomyelitis was unrelated to
prosthesis in 224 (51.9 %) patients, while in 208 (48.1 %)
patients, the disease was related to either a permanent (n=
160; 37.0 %) or temporary (n=48; 11.1 %) prosthetic device.
The most common sites of infection were the knee (n=171;
26.8 %), hip (n=147; 23.0 %), lower extremity (n=94;
14.7 %), foot/ankle (n=83; 13.0 %), and back (n=65;
10.2 %). The most common prosthetic joints were the pros-
thetic knee (40.4 %) and prosthetic hip (26.6 %). Patient de-
mographics and clinical characteristics including the most
common underlying diseases are summarized in Table 1.
Microbiology
Culture results were available for 534 (83.7 %) patients and
were found positive for 436 (81.6 %) of them. The most fre-
quently isolated pathogen was S. aureus (n=214; 49.1 %, of
which 50.5 % were MRSA), followed by CoNS species (n=
Table 1 Demographic and clinical characteristics (safety population)
Characteristics Patients (N=638)
[n (%)]




Permanent prosthetic device-related 160 (37.0)
Temporary prosthetic device-related 48 (11.1)











Renal function [n (%)]
Severe renal impairment (CrCl <30 mL/min)
at initiation of daptomycin therapy
46 (7.2)
Patients on dialysis at daptomycin initiation 15 (2.4)
Significant underlying diseases (>5 %) [n (%)]
Cardiovascular disease 276 (43.3)
Diabetes mellitus 140 (21.9)
Fractures 101 (15.8)
Pulmonary disease 54 (8.5)
Gastrointestinal disease 52 (8.2)
Renal disease 48 (7.5)
Immunologic/Inflammatory disease 46 (7.2)
Oncologic disease 44 (6.9)
Anatomical site of infection (>5 %) [n (%)]
Knee 171 (26.8)
Hip 147 (23.0)
Lower extremity 94 (14.7)
Foot/ankle 83 (13.0)
Back 65 (10.2)
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153; 35.1 %). The main culture sources of primary pathogens
were deep culture tissue (n=199; 31.2 %), blood (n=93;
14.6 %), bone (n=91; 14.3 %), skin swabs (n=52; 8.2 %),
needle aspirates (n=40; 6.3 %), and intraoperative tissue bi-
opsies (n=14; 2.2 %). The culture results in the study popu-
lation are described in Table 2.
Prior and concomitant antibiotic therapies
A total of 455 (71.3 %) patients received antibiotic therapy
prior to daptomycin treatment. Glycopeptides (n=220;
34.5 %) were most frequently used, followed by
fluoroquinolones (n=151; 23.7 %) and penicillins (n=126;
19.7 %). The main reason for a switch to daptomycin therapy
was failure (n=190, 29.8 %) of the previous antibiotic. A total
of 372 (58.3 %) inpatients and 116 (18.2 %) outpatients re-
ceived antibiotics concomitantly with daptomycin therapy.
Fluoroquinolones and carbapenems were the most common
antibiotics used concomitantly with daptomycin.
Daptomycin prescribing patterns
Initial doses of 6 mg/kg/day of daptomycin were most fre-
quently prescribed (n=276; 43.3 %), followed by ≥8 to
≤10 mg/kg/day (n=114; 17.9 %), >6 to <8 mg/kg/day (n=
92; 14.4 %), and 4 mg/kg/day (n=82; 12.9 %). The other
prescribed doses were >4 to <6 mg/kg/day received by 42
(6.6 %) patients and >10 mg/kg/day received by 14 (2.2 %)
patients. The initial dosage was unknown for 18 (2.8 %) pa-
tients. The median duration of daptomycin therapy was
20 days (range, 1–246). On the basis of patient disposition,
the median duration of therapy was 14 days (range, 1–246) for
inpatients, 27 days (range, 2–176) for outpatients, and 6 days
(range, 1–44) for intensive/critical care patients. The median
duration of therapy by type of primary infection was 21 days
(range, 1–246) for osteomyelitis and 16 days (range, 1–176)
for orthopaedic device infections. A trend towards the use of
higher doses over time was noted in the treatment of osteomy-
elitis and orthopaedic device infections (Fig. 1).
Surgical interventions
The majority of patients underwent surgery during daptomycin
therapy, most commonly tissue/bone debridement (Table 3).
Data on the prosthetic device involved and surgical approach
were available in a small proportion of patients (Table 4).
Clinical outcomes
Overall, clinical success with daptomycin therapy was
achieved in 522 (81.8 %) patients. The clinical outcomes by
type and subtype of primary infection are summarized in
Fig. 2. Clinical success rates were highest in patients with a
temporary prosthetic device (89.6 %) as compared with non-
prosthetic (79.9 %) and permanent prosthetic device-related
osteomyelitis (78.1 %). Clinical success rates were similarly
high in patients with S. aureus (82.7 %) and CoNS (81.7 %)
infections (Fig. 3). Furthermore, high rates of clinical success
were observed with both first-line (80.1 %) and second-line
daptomycin treatment (83.1 %). Of 318 (49.8 %) patients with
data on time to improvement, median time to improvement
was 6 days (range, 1–90). Patients receiving daptomycin in
combination with rifampin showed numerically higher suc-
cess rate (n=121; 86.8 %) to those who did not receive
Table 2 Primary pathogens in patients with positive cultures
Primary pathogens Patients with positive
cultures (N=436)
[n (%)]
Staphylococcus aureus 214 (49.1)
Methicillin-resistant 108 (24.8)
Methicillin-susceptible 88 (20.2)
Methicillin susceptibility unknown 18 (4.1)
Coagulase-negative Staphylococcus species 153 (35.1)
Staphylococcus epidermidis 104 (23.9)
Other 49 (11.2)
Streptococcus agalactiae or group B streptococci 5 (1.1)
Streptococcus pyogenes or group A streptococci 3 (0.7)
Viridans streptococci group 3 (0.7)
Staphylococcus species - coagulase not specified 4 (0.9)
Enteroccoccus faecalis 19 (4.4)




Enteroccoccus species 3 (0.7)
Othera 25 (5.7)
a Includes Corynebacterium species, Streptococcus dysgalactiae,
Streptococcus species, Gram-positive bacilli, Gram-positive cocci, and
Gram-negative bacilli
Fig. 1 High dose daptomycin use over time in patients with
osteomyelitis or foreign body prosthetic infections
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rifampin concomitantly (n=401; 80.3 %). Long-term follow-
up data were collected from a total of 290 patients. Clinical
success in patients followed for up to 2 years was 85.8 %.
Most patients (81.3 %) remained relapse-free until the end of
the 2-year follow-up period (Fig. 4).
Safety
Daptomycin-related AEs and SAEswere reported in 43 (6.7%)
and 12 (1.9 %) patients, respectively. Discontinuation of dap-
tomycin due to AEs was reported in 35 (5.5 %) patients and
there were ten (1.6 %) deaths (unrelated to study medication)
during the study period. The incidence of AEs and SAEs dur-
ing daptomycin treatment is described in Table 5. Three (0.5%)
patients experienced rhabdomyolysis (two moderate cases and
one severe case); all these three events were considered by the
investigator as possibly related to daptomycin and two cases
were reported as SAEs.
Serum creatine phosphokinase (CPK) elevation was mea-
sured at baseline for 352 (55.2 %) patients and the majority
(n=313, 88.9 %) had normal CPK values. Three patients ex-
perienced a shift in CPK elevation with a normal value at
baseline to >10×ULN post-baseline. Eleven (1.7 %) patients
had elevated CPK levels and were considered by the investi-
gator as AEs related to daptomycin. Of these, 8 (1.3 %) pa-
tients discontinued the study drug. The highest CPK levels
measured during therapy were reported as normal in most of
the patients (n=323, 80.5 %), and above ULN in 78 (24.1 %)
patients. Median time for highest CPK was 10 days after
starting daptomycin treatment.
Discussion
In the present analysis, 432 patients with osteomyelitis (non-
prosthetic and prosthetic device-related) and 206 patients with
Table 3 Surgical interventions during daptomycin therapy
Interventions Patients (N=638)
[n (%)]a
Tissue debridement 225 (35.3)
Bone debridement 196 (30.7)
Foreign device removed 173 (27.1)





a Patients may have had more than one surgical intervention
Table 4 Prosthetic device involved and surgical approach




Prosthetic joint 63 (67.0)
Knee 38 (40.4)
Hip 25 (26.6)




Invalid/missing device code (1.1)
Surgical approach
Removal without re-implantation 22 (23.4)
Debridement and retention 17 (18.1)
Two-stage exchange 14 (14.9)
One-stage exchange 3 (3.2)
Amputation 2 (2.1)
No surgical approach 36 (38.3)
Fig. 2 Clinical success rates by primary infection
Fig. 3 Clinical outcomes by infecting pathogen. CoNS coagulase-
negative staphylococci, MRSA methicillin-resistant Staphylococcus
aureus, MSSA methicillin-susceptible Staphylococcus aureus
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orthopaedic device infections were treated with daptomycin.
The knee and the hip were the most common sites of prosthet-
ic or orthopaedic device-related infection. Two-thirds of pa-
tients with supplementary data underwent surgery as part of
their treatment. S. aureus was the most frequently isolated
pathogen, of which >50 % were methicillin-resistant. The
most frequently prescribed dose of daptomycin was
6 mg/kg/day and high-dose daptomycin (>6 mg/kg/day) was
used in one-third of the total number of patients.
The study results indicate that overall clinical success rates
were high in patients with osteomyelitis (non-prosthetic and pros-
thetic device-related) and orthopaedic device infections. The ma-
jority of patientswith non-prosthetic and prosthetic device-related
osteomyelitis and orthopaedic device infections, inwhom follow-
up data were available, remained relapse-free up to 2 years.
Whilst a variety of microbial and host factors are responsible
for the development of osteomyelitis, S. aureus is the most
commonly involved pathogen [6]. Single-agent antimicrobial
therapy is generally adequate for the treatment of non-
prosthetic device-related osteomyelitis compared to prosthetic
device-related osteomyelitis, for which antibacterial combina-
tion including rifampicin is commonly used [7]. Infections as-
sociated with prosthetic joints cause significant morbidity and
account for a substantial proportion of health care expenditures
[25]. Despite the use of various oral and parenteral antibiotics
against relevant Gram-positive pathogens, treatment remains
challenging and relapse rates are high after seemingly success-
ful antibiotic treatment [9, 26]. Osteomyelitis relapses can result
from the persistence of a foreign body or incomplete surgical
debridement of bone sequestra [7].
Rifampin has excellent oral bioavailability, tissue penetra-
tion, and activity in biofilms, and has been extensively used
for staphylococcal osteomyelitis in combination with a variety
of antimicrobial agents [9]. Daptomycin combinedwith rifam-
pin is a promising treatment option for implant-associated
MRSA infections [15]. To achieve higher success rates, sur-
gical treatment should be combined with a prolonged antibi-
otic treatment [10, 25]. The optimal dose of daptomycin for
treating osteomyelitis and orthopaedic device infections is yet
to be defined.
Daptomycin concentrations of 64 μg/ml have demonstrat-
ed improved activity against staphylococci embedded in
biofilms [27]. High-dose daptomycin (30 mg/kg/day) in guin-
ea pigs, corresponding to 6 mg/kg/day in humans, combined
with rifampin (12.5 mg/kg/day) showed superior efficacy
against both planktonic and adherent MRSA infections over
vancomycin plus rifampin and linezolid plus rifampin combi-
nation therapies, and prevented the emergence of rifampin
resistance [28].
The clinical efficacy of daptomycin in osteomyelitis is sup-
ported by its pharmacokinetic and pharmacodynamic profile.
The IDSA guidelines for management of osteomyelitis and
prosthetic joint infections recommend daptomycin as an alter-
native treatment option [21, 22]. High clinical success rates
have been reported in patients treated with daptomycin for
osteomyelitis in previous studies [18, 19]. Available data sup-
port the use of higher doses of daptomycin (8–10mg/kg/day) in
combination with a second drug (usually rifampin) in order to
optimize its activity and avoid the emergence of resistance [29].
A favourable safety profile was observed in patients with
osteomyelitis and orthopaedic device infections in this analysis.
Although serum CPK elevation with daptomycin is well doc-
umented, minimal cases were observed in this study and the
incidence of muscle related AE was very low. Observational
registries have several advantages over other studies, given
their inclusive design and ability to demonstrate the real-
world clinical experience of treatment. However, they also have
limitations such as not being able to control various factors that
Fig. 4 Long-term follow-up of osteomyelitis (non-prosthetic and
prosthetic device-related) and orthopaedic device infections; Time to
relapse
Table 5 Adverse events, serious adverse events and deaths during
treatment with daptomycin
Safety parameters Patients (N=638)
[n (%)]
Any AE(s) 78 (12.2)
AE(s) leading to permanent drug discontinuation 35 (5.5)
AEs related to daptomycin 43 (6.7)




AEs occurring in >1 % patients, n (%)
Blood CPK increased 11 (1.7)
Any SAE(s) 39 (6.1)
SAE related to daptomycin 12 (1.9)
Deaths 10 (1.6)
AE adverse event, CPK creatine phosphokinase, SAE serious adverse
event
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could influence the treatment outcome. These factors could be
the duration of antimicrobial therapy, surgical management
strategies, or prior and concomitant antibiotic therapy.
Based on the results of this analysis, daptomycin was found
to be effective and safe in patients with osteomyelitis or or-
thopaedic device infections.
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